ESCRS Homepage

March 2003
IN THIS ISSUE

New ESCRS trial in bid to cut endophthalmitis rate to 0.01%


Lasik corrects refractive errors after PK in selected patients

Africa-Luz mobilises to provide eye care in regions riven by poverty

Multifocal IOL
choice hinges on patterns of daily routine

Anti-histamine drug mitigates risk of developing DLK after Lasik, says study

Untreated eyelid inflammatory disorders pose risk for postoperative complications

Thermotopography shows ‘enormous promise’
for diagnosis and treatment of eye diseases

Lasik offers ‘very effective treatment’ for
refractive errors after PK, says US specialist

Good results with PRK and Lasek rival Lasik for top spot in refractive excimer laser surgery

Orbital lymphomas respond well to local, systemic therapies, says study

Laser technologies still beam but economy and consumer demand will determine future of refractive surgery

Legally blind cardiologist finds new beat in low vision rehabilitation

‘Pivotal’ anti-TGF antibody therapy reduces
filtering bleb wound formation, says report

Neuroprotective agents stem optic nerve damage
by ‘offering a solution’ to open-angle glaucoma

Echothiophate iodide shortage leaves US specialists struggling to find alternative for acute cases

Postoperative complications of PK will have serious consequences unless tackled 'aggressively’

Private refractive clinics claim young specialists as public waiting lists grow in Canadian eye surgery

German doctors’ helpers oil the cogs of the private ophthalmic practice

Study of 900 ICLs reveals good safety and long-term refractive results, says Spanish specialist

New toric IOL corrects high corneal astigmatism after cataract surgery, Austrian study reveals

IVF children run increased risk of developing
retinoblastoma, claim Dutch researchers

Suture-free DLEK preserves corneal surface topography and ensures faster wound healing

The day I said goodbye to cataracts and hello to the world without glasses

Retina specialists and trauma ophthalmologists
prepare to trade notes at joint Hungarian conference

Night blindness casts bogeyman into the shadows

Erbium laser phaco requires longer time but less energy for moderately hard cataracts

FEATURES
From The Editor
Reflections on Refractive Surgery
In Your Good Books
Bio-ophthalmology
In The Driving Seat
Prime Site
The Collector's Eye
Regulatory Matters



Multifocal IOL choice hinges on patterns of daily routine

Roibeard O’hÉineacháin
in Rome

DECIDING which multifocal IOL to implant may depend on a patient’s lifestyle requirements, according to a German ophthalmologist.
In a study involving 40 cataract patients who underwent bilateral implantation of either of two types of multifocal IOL, the AMO Array or the IOLtech MF-4, those with the Array lens achieved better distance UCVA while those with the MF-4 achieved better near UCVA, Magda Rau MD told the seventh ESCRS Winter Refractive Surgery Meeting.

“Following our experience, we now offer the AMO Array lens to younger and more active patients and the MF-4 lens to those who are older and less mobile, with higher expectations for near vision,” Dr Rau said.
The mean UCVA for distance vision was 0.72 for the AMO Array lens and 0.63 for the MF-4-group. The mean UCVA for near vision was 0.72 for the AMO Array group and 0.78 for the MF-4 one.

In the AMO group, 60% had a UCVA for distance of 20/25 or better, compared to only 20% in the MF-4 group. BCVA for distance was 20/25 or better in 87% of the AMO group, compared to only 51% in the MF-4 group.
In the MF-4 group, 52% had a UCVA for near of 20/25 or better, compared to only 33% of those in the AMO group. All patients in the MT-4 group and 96% of those in the AMO group achieved a near BCVA of 20/25 or better.
In the AMO group 65% still used glasses, although 55% used them only occasionally and 10% used them constantly. In the MF-4 cohort, 50% still used glasses, 48% only occasionally and 2% constantly.

The incidence of optic phenomena was similar with both lenses. In the AMO group, 35% reported glare and 70% reported halos. In the MF-4 group, 25% reported glare and 65% reported halos.
The mean contrast sensitivity, tested with a Pelli-Robson chart, was 1.62 in the AMO-Array group and 1.56 in the MF-4 group.
The AMO Array (AMO-Allergan) is a foldable silicone lens, with five annular concentric zones, three for distance and two for near vision.

The Autofocus-Lens MF-4 (IOLtech) is a foldable hydrophilic acrylic-lens with four annular concentric zones, two for distance vision and two for near vision.
Dr Rau suggested that the better performance at distance and near for the Array and MF-4 lenses respectively might be due to their different optical designs.
The centre zone of the AMO lens focuses for distance, and the lens therefore emphasises the distance image while the central zone of the MT-4 lens focuses for near and therefore emphasises the near image.

“Both lenses provide very good near and distance visual acuity results and a high degree of patient satisfaction. According to their design, the visual acuity for distance vision is better with the AMO Array and the visual acuity for near vision is better with the MF-4,” Dr Rau explained.
She has recently begun to implant both types of IOL in alternate eyes of the same patient to provide vision optimised for distance in one eye and for near in the other.
“Having access to both lenses gives the surgeon the possibility of satisfying a larger share of patients,” she said.

Magda Rau MD
Tagesklinik, Cham, Germany
Email: rau@augenklinik-cham.de

 

Top